Showing results (111-120 of 140) with videos related to

Sort By:
Pageof 14
Current Microbiology|January 21, 2010
Molecular characterisation of the faecal microbiota in patients with type II diabetesXiaokang Wu, Chaofeng Ma, Lei Han, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 8, 2024
Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trialZhichao Jiang, Yibin Xie, Wen Zhang, et al.
Frontiers in Oncology|February 22, 2020
Hexokinase 2 Depletion Confers Sensitization to Metformin and Inhibits Glycolysis in Lung Squamous Cell CarcinomaWenzheng Guo, Yanbin Kuang, Jingjing Wu, et al.
Molecular Cancer|May 10, 2024
Minimal residual disease profiling predicts pathological complete response in esophageal squamous cell carcinomaPinli Yue, Fenglong Bie, Jiarun Zhu, et al.
European Urology Open Science|November 8, 2024
Dynamic Changes in Serum Immunoglobulin G Predict Clinical Response and Prognosis in Metastatic Clear-cell Renal Cell CarcinomaHonglei Cui, Jie Wu, Gan Du, et al.
Hepatology International|September 14, 2023
The MAPS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with targeted therapy plus immunotherapyJingzhong Ouyang, Yi Yang, Yanzhao Zhou, et al.
Cancer Medicine|November 29, 2023
Neutrophil extracellular traps in relationship to efficacy of systemic therapy for metastatic renal cell carcinomaRuiyang Xie, Bingqing Shang, Hongzhe Shi, et al.
Cancer Science|October 13, 2020
Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinomaDingwei Ye, Jiyan Liu, Aiping Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2020
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial CarcinomaXinan Sheng, Xieqiao Yan, Lin Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|May 21, 2024
A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinomaWang Qu, Cheng Fu, Weiqing Han, et al.
Pageof 14